Fully automatic HER2 tissue segmentation for interpretable HER2 scoring by Mathias Öttl, Jana Steenpass, Frauke Wilm, Jingna Qiu, Matthias Rübner, Corinna Lang-Schwarz, Cecilia Taverna, Francesca Tava, Arndt Hartmann, Hanna Huebner, Matthias W. Beckmann, Peter A. Fasching, Andreas Maier, Ramona Erber, Katharina Breininger

Subjects: “…HER2…”
Get full text

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? by Yu Ishimine, Akira Goto, Yoshito Watanabe, Hidetaka Yajima, Suguru Nakagaki, Takashi Yabana, Takeya Adachi, Yoshihiro Kondo, Kiyoshi Kasai

“…Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. …”
Get full text

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients by Gokce Deniz Ardor, Miglena K. Komforti, Helena Hanna, Onur Ibanoglu, Abigail Lochala, Aziza Nassar

“…Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. …”
Get full text

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. by Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett

“…HER2 is over-expressed in around 15% to 20% of breast cancers. …”
Get full text

Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer by Taeyeong Kim, Seung Taek Lim, Hyang Suk Choi, In-Jeong Cho, Hany Noh, Jong-In Lee, Airi Han

Subjects: Get full text

Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status by Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung

“…Abstract We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I–III). …”
Get full text

Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category by Ana Catharina Joaquim, Lucas Kliemann Bazzaneze, Ana Paula Percicote, Ana Paula Martins Sebastião

Subjects: “…HER2…”
Get full text

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer by Abbey Zidel, Alex Benton, Emma Brown, Shayla Shmuel, Alex Vanover, Sandeep Surendra Panikar, Ron Bose, Haeseong Park, Andrew A. Davis, Patrícia M. R. Pereira

Subjects: “…HER2…”
Get full text

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE by A. N. Stukov, S. F. Vershinina, N. A. Koziavin, T. Yu. Semiglazova, L. V. Filatova, D. Kh. Latipova, A. O. Ivantsov, V. G. Bespalov, A. L. Semenov, O. A. Belyaeva, G. S. Kireeva, V. A. Alexandrov, G. V. Tochilnikov, I. N. Vasilyeva, M. A. Maydin, M. L. Tyndyk, S. S. Kruglov, G. A. Yanus, V. N. Yurova

Subjects: “…her2-positive breast cancer…”
Get full text

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis by Yoonwon Kook, Young-jin Lee, Chihhao Chu, Ji Soo Jang, Seung Ho Baek, Soong June Bae, Yoon Jin Cha, Gyungyup Gong, Joon Jeong, Sae Byul Lee, Sung Gwe Ahn

Get full text

Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET/CT radiomics by Xuefeng Hou, Kun Chen, Huiwen Luo, Wengui Xu, Xiaofeng Li

Subjects: Get full text

Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups by Erkan Ozcan, Ivo Gokmen, Fahri Akgul, Fatma Akdag Kahvecioglu, Abdussamet Celebi, Osman Kostek, Ilhan Hacıbekiroglu, Bulent Erdogan

“…Conclusion: HER2 status did not significantly impact treatment outcomes with CDK4/6i in HR+/HER2-negative MBC patients. …”
Get full text

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. by Qiuyan Yu, Zhenli Zhu, Yan Liu, Jun Zhang, Ke Li

“…<h4>Background</h4>Clinical trials of human epidermal growth factor receptor 2 (HER2)-targeted agents added to standard treatment have been efficacious for HER2-positive (HER2+) advanced breast cancer. …”
Get full text

PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer by Xin Zhao, Yang Li, Hongyan Zhang, Yihang Cai, Xu Wang, Yidu Liu, Tingting Li, Chendong Xu, Yuee Teng, Danni Li, Feng Li

“…Abstract Nuclear HER2 (N-HER2) predicts resistance to HER2-targeted therapy and poor prognosis of breast cancer patients, and the underlying mechanisms remain unclear. …”
Get full text

Correction: HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. by PLOS ONE Staff

Get full text

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade by V. F. Semiglazov, N. B. Bekkeldieva, P. V. Krivorotko, A. V. Komyakhov, R. M. Paltuev, A. I. Tseluyko, L. P. Gigolaeva, T. T. Tabagua, E. K. Zhiltsova, V. S. Apollonova, G. A. Dashyan, A. G. Kudaybergenova, V. G. Ivanov, A. A. Bozhok, D. G. Ulrikh, A. O. Gorina, T. Yu. Semiglazova

Subjects: “…her2-positive breast cancer…”
Get full text

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer by Karam Aboud, Magda Meissner, Rob Jones

“…Notably, Capivasertib plus Fulvestrant received Food and Drug Administration (FDA) approval in 2023 for ER-positive/HER2-negative breast cancer with PI3K/AKT/PTEN alterations. …”
Get full text

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients by Zohreh Gheibipour, Tina Vosoughi, Gholamreza Shariati, Mehran Hoseinzadeh, Mohammad Reza Mahmoudian-Sani, Mahdi Bijanzadeh

Subjects: “…HER2-positive breast cancer…”
Get full text

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy by Rumeysa Colak, Caner Kapar, Ezgi Degerli, Seher Yildiz Tacar, Aysegul Akdogan Gemici, Nursadan Gergerlioglu, Serdar Altinay, Mesut Yilmaz

Subjects: “…HER2-low…”
Get full text

HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups by Karoliina Aro, Mikko Loukovaara, Ralf Bützow, Annukka Pasanen

“…Abstract Background Emerging HER2-targeted therapies provide new treatment options for patients with HER2-expressing tumors. …”
Get full text